IFNGR1 and neoplasm: These in vivo data further support a mechanism by which hyperactive mTORC1 signaling in RAC1A159V tumors attenuates ICI efficacy through increased tumor glycolysis, suppressed chemokine production, and down-regulated IFNGR1 expression.